TCL Archive AVEO’s Tivozanib Sunk by Fundamental Flaw: Higher Overall Survival in the Control Arm May 8, 2013
TCL Archive Gregory Reaman Named Associate Director of FDA Office of Oncology Drug Products June 3, 2011
TCL Archive FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate. May 28, 2004
